Content about Bristol

May 8, 2013
Healthcare reform law provisions could affect pharmaceutical innovation, Bristol-Myers Squibb exec says

Drug maker Bristol-Myers Squibb foresees significant effects on its business from the Patient Protection and Affordable Care Act, company executives told attendees of its recent shareholder meeting.

September 18, 2012
Record patent expirations roil Rx market

For branded drug makers, the pharmaceutical patent cliff has never loomed higher or steeper. The exposure of so many of the world’s biggest-selling medicines to generic competition for the first time is redefining the pricing model for many of the most widely prescribed classes of pharmaceuticals.

August 9, 2012
Bristol-Myers Squibb, AstraZeneca expand diabetes deal

AstraZeneca paid $3.2 billion to Amylin Pharmaceuticals Thursday following the latter's acquisition by Bristol-Myers Squibb, AstraZeneca and Bristol said.

August 8, 2012
Bristol-Myers Squibb purchase of Amylin mostly complete, company says

Bristol-Myers Squibb has bought a majority stake in drug maker Amylin Pharmaceuticals, Bristol said Wednesday.

July 9, 2012
FDA approves Lilly, BMS drug for KRAS wild-type colorectal cancer

The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

July 2, 2012
Bristol-Myers Squibb buys Amylin for $5.3 billion

Bristol-Myers Squibb is acquiring Amylin Pharmaceuticals, the drug maker said Friday.

May 2, 2012
GNC signed as presenting sponsor at ESPN's 2012 ESPNHS Games

ESPN on Wednesday announced that GNC will headline the 2012 ESPNHS Games as presenting sponsor.

March 15, 2012
Price Chopper takes savings to the 'xtreme'

Price Chopper is calling out products that tout value through a new display concept.

February 14, 2012
Bristol-Myers Squibb completes Inhibitex acquisition

Bristol-Myers Squibb has completed its acquisition of a developer of hepatitis C treatments.

February 3, 2012
Regulatory waiting period for Bristol's Inhibitex acquisition expires

The regulatory waiting period standing between Bristol-Myers Squibb and its acquisition of drug maker Inhibitex has expired, giving Bristol the green light to buy the company.

January 20, 2012
Bristol-Myers Squibb donates $6.9 million to benefit cancer patients

Drug maker Bristol-Myers Squibb has donated $6.9 million to a nonprofit group that helps people pay for medical treatments, the company said.

January 19, 2012
Bristol-Myers Squibb, AstraZeneca diabetes drug hits speed bump at FDA

The Food and Drug Administration has declined to approve a drug for Type 2 diabetes made by Bristol-Myers Squibb and AstraZeneca, saying it needs additional clinical data, the companies said Thursday.

January 13, 2012
Bristol-Myers Squibb commences tender offer for Inhibitex

Bristol-Myers Squibb has officially launched its tender offer for Inhibitex, the drug maker said Friday.

January 9, 2012
Bristol-Myers Squibb to acquire Inhibitex

Bristol-Myers Squibb is buying Inhibitex for $2.5 billion, the companies said.

January 3, 2012
Teva leader to exit company in May, former Bristol executive to step in

Teva Pharmaceutical Industries announced that Shlomo Yanai, president and CEO, will retire from his post in May.

December 23, 2011
Bristol-Myers Squibb, Gladstone Institutes to collaborate on Alzheimer's drug discovery

Drug maker Bristol-Myers Squibb and the Gladstone Institutes will collaborate to find new ways to treat Alzheimer's disease, the two said Thursday.

November 3, 2011
BMS to present abstracts from Orencia studies at American College of Rheumatology meeting

Drug maker Bristol-Myers Squibb will present 20 study abstracts at the American College of Rheumatology Annual Scientific Meeting in Chicago, the company said Thursday.

October 27, 2011
Bristol-Myers Squibb, Gilead Sciences to develop, commercialize HIV combo treatment

Drug makers Bristol-Myers Squibb and Gilead Sciences announced an agreement to develop and commercialize a fixed-dose combination treatment for patients with HIV.

October 20, 2011
Bristol-Myers Squibb announces executive changes

Bristol-Myers Squibb announced changes to its senior management team, including the appointment of its U.S. pharmaceuticals president.

September 22, 2011
BMS, Ambrx ink deal to research, develop, commercialize diabetes, heart failure biologics

Two drug makers have entered a collaboration for novel biologics programs in diabetes and heart failure.

August 1, 2011
FDA approves subcutaneous formulation of Orencia

The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for injection under the skin to treat rheumatoid arthritis, Bristol said Friday.

July 22, 2011
Bristol to acquire Amira

Bristol-Myers Squibb will acquire San Diego-based Amira Pharmaceuticals for $325 million, the two companies said Friday.

July 19, 2011
Graceway receives regulatory approval for Zyclara

The Food and Drug Administration has approved a drug made by Graceway Pharmaceuticals for actinic keratoses, Graceway said.

March 30, 2011
Dr. Reddy's completes acquisition of U.S. penicillin facility, products from GSK

Dr. Reddy’s Labs will assume ownership of a penicillin manufacturing site in Bristol, Tenn., from GlaxoSmithKline.

March 28, 2011
FDA approves topical treatment for genital warts

The Food and Drug Administration has approved a topical treatment for genital warts made by Graceway Pharmaceuticals, the drug maker said Monday.

© 2013 Drug Store News. All Rights Reserved.